Greenwich LifeSciences
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Greenwich LifeSciences generated cash of -$6,478,602, which is less than the previous year. Cash used in financing activities reached the amount of $0 last year. Net change in cash is therefore -$6,478,602.
Cash Flow
| 2017 | -120.84K | 0 | -129.84K |
|---|---|---|---|
| 2018 | -114.95K | 0 | 200K |
| 2019 | -293.26K | 0 | 215K |
| 2020 | -1.15M | 0 | 29.80M |
| 2021 | -4.29M | 0 | 2.83M |
| 2022 | -6.20M | 0 | -7.53M |
| 2023 | -6.47M | 0 | 0 |
GLSI Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 13.46M | 27.20M | 28.66M | 6.83K | 85.10K | 54 | 250.74K |
Operating activities | |||||||
Net income | -8.89M | -7.82M | -4.57M | -1.86M | -3.42M | -1.68M | -1.57M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 3.61K | 3.61K | 3.61K | 3.60K | 3.60K | 3.60K | 3.60K |
Stock-based compensation expense | 2.37M | 1.74M | 660.58K | 677.98K | 194.94K | 0 | 0 |
| Deferred income tax benefit | 2.37M | 1.74M | 660.58K | 677.98K | 194.94K | 0 | 0 |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 35.47K | 0 | -526.73K | -92.55K | 393.40K | 80.96K | 144.91K |
Cash generated by operating activities | -6.47M | -6.20M | -4.29M | -1.15M | -293.26K | -114.95K | -120.84K |
Investing activities | |||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Financing activities | |||||||
Common Stock Issued | 0 | 0 | 3.11M | 30.16M | 0 | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | -7.53M | 0 | 0 | 0 | 0 | -90K |
Repayments of term debt | 0 | 0 | 0 | -360K | 0 | 0 | 0 |
Cash used in financing activities | 0 | -7.53M | 2.83M | 29.80M | 215K | 200K | -129.84K |
Net Change In Cash | -6.47M | -13.73M | -1.45M | 28.65M | -78.26K | 85.04K | -250.69K |
Cash at end of period | 6.98M | 13.46M | 27.20M | 28.66M | 6.83K | 85.10K | 54 |
| Data source | Data source | Data source | Data source |